NASDAQ:NEUP Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis $3.65 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.65 0.00 (0.00%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Neuphoria Therapeutics Stock (NASDAQ:NEUP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neuphoria Therapeutics alerts:Sign Up Key Stats Today's Range$3.65▼$3.6950-Day Range$3.33▼$3.9852-Week Range$3.19▼$21.40Volume2,878 shsAverage Volume18,420 shsMarket Capitalization$19.75 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingReduce Company Overview Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and other metabolic diseases. The company’s research programs are designed to address conditions involving weight management, diabetes and metabolic dysfunction. Neuphoria’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed for obesity and related metabolic conditions. The company is also developing DA-1241, an investigational GPR119 agonist intended for metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis, and other metabolic disorders. These programs originated through collaborations and licensing arrangements with Dong-A-related entities. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and adopted the Neuphoria Therapeutics name as its business focus evolved toward metabolic disease therapies. As a clinical-stage company, Neuphoria does not yet have an established portfolio of commercially marketed products. Its programs remain subject to clinical development, regulatory review and potential approval.AI Generated. May Contain Errors. Read More Neuphoria Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreNEUP MarketRank™: Neuphoria Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 520th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingNeuphoria Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialNeuphoria Therapeutics has a consensus price target of $7.00, representing about 91.8% upside from its current price of $3.65.Amount of Analyst CoverageNeuphoria Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Neuphoria Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Neuphoria Therapeutics are expected to decrease in the coming year, from ($2.43) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuphoria Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuphoria Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuphoria Therapeutics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neuphoria Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.46% of the float of Neuphoria Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuphoria Therapeutics has a short interest ratio ("days to cover") of 1.22, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuphoria Therapeutics has recently decreased by 61.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuphoria Therapeutics does not currently pay a dividend.Dividend GrowthNeuphoria Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.76 News SentimentNeuphoria Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Neuphoria Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.55% of the stock of Neuphoria Therapeutics is held by insiders.Percentage Held by Institutions15.90% of the stock of Neuphoria Therapeutics is held by institutions.Read more about Neuphoria Therapeutics' insider trading history. Receive NEUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuphoria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEUP Stock News HeadlinesNeuphoria Therapeutics (NEUP) Set to Post Earnings on MondaySeptember 28 at 1:58 AM | americanbankingnews.comNeuphoria Therapeutics Inc. (NASDAQ:NEUP) Stock Short Interest Falls 61.8%September 27 at 3:01 AM | americanbankingnews.comThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company the same size Nvidia was a decade ago. Brown says this firm's patented technology can produce intelligence up to 1,000 times faster than standard AI, and he expects Elon Musk to fuel demand starting November 11. The technology is protected by 150 patents.September 28 at 1:00 AM | Brownstone Research (Ad)IDEAYA Biosciences (NASDAQ:IDYA) vs. Neuphoria Therapeutics (NASDAQ:NEUP) Financial ComparisonSeptember 21, 2026 | americanbankingnews.comNeuphoria Therapeutics Inc. Reports Earnings Results for the Full Year Ended June 30, 2026September 19, 2026 | marketscreener.comMNeuphoria Therapeutics Inc Ordinary Shares NEUPAugust 14, 2026 | morningstar.comMNeuphoria Therapeutics Inc (NEUP)August 8, 2026 | investing.comThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAXJuly 30, 2026 | globenewswire.comSee More Headlines NEUP Stock Analysis - Frequently Asked Questions How have NEUP shares performed this year? Neuphoria Therapeutics' stock was trading at $3.88 on January 1st, 2026. Since then, NEUP stock has decreased by 5.9% and is now trading at $3.65. How were Neuphoria Therapeutics' earnings last quarter? Neuphoria Therapeutics Inc. (NASDAQ:NEUP) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.47. Who are Neuphoria Therapeutics' major shareholders? Top institutional investors of Neuphoria Therapeutics include ADAR1 Capital Management LLC (0.56%) and Merck & Co. Inc. (0.19%). View institutional ownership trends. How do I buy shares of Neuphoria Therapeutics? Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today9/28/2026Next Earnings (Estimated)10/05/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (11m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NEUP's financial health is in the Yellow zone, according to TradeSmith. NEUP has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NEUP Previous SymbolNASDAQ:NEUP CIK1191070 Webwww.neuphoriatx.com Phone(781) 439-5551FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Price Target for Neuphoria Therapeutics$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+91.8%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($6.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.45 million Net MarginsN/A Pretax Margin-1,157.67% Return on Equity-38.31% Return on Assets-28.92% Debt Debt-to-Equity RatioN/A Current Ratio27.83 Quick Ratio27.83 Sales & Book Value Annual Sales$1.17 million Price / Sales16.88 Cash FlowN/A Price / Cash FlowN/A Book Value$4.55 per share Price / Book0.80Miscellaneous Outstanding Shares5,410,000Free Float5,327,000Market Cap$19.75 million OptionableN/A Beta0.75 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:NEUP) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
